HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category HeartSciences (Nasdaq: HSCS) announced that its MyoVista Insights platform received Epic Toolbox designation for the ECG Management System category on March 25, 2026. The cloud-native platform supports HL7v2 order/results, SSO, and SMART on FHIR to integrate with Epic EHR workflows.This designation signals that MyoVista Insights meets Epic’s recommended practices for ECG integrations and is listed on Epic Showroom, enabling clinicians to access the platform within existing EHR workflows.

#HSCS #HSCSW HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

www.stocktitan.net/news/HSCS/heart-sciences...

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update HeartSciences (Nasdaq: HSCS) reported fiscal Q3 2026 results and a business update. The company has no meaningful revenue for FQ3, reported $3.4M cash and $2.7M shareholders' equity as of Jan 31, 2026, and advanced commercialization of its MyoVista Insights platform.Key operational milestones include an MDDS regulatory classification for MyoVista Insights, a significant platform upgrade released March 13, 2026, and a December 2025 FDA 510(k) submission for the MyoVista wavECG device.

#HSCS #HSCSW HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

www.stocktitan.net/news/HSCS/heart-sciences...

🔔 Issue 4 of 2026 is live! Featuring:

🩸 Perspective: Aging of haematopoietic stem cells #HSCs
🔬 Review and original research on #genome organization
👨‍🔬 The Scientists' Forum: Effective collaboration in the Life Sciences
📡 Plus #enzymology, #biophysics, and plant biology 🌿

▶️ tinyurl.com/4hd2brwy

"Inflammaging" is unavoidable, but does nature have a way to slow it down?

In Dr. Lev Silberstein’s lab at @fredhutch.org, Dorsa Toghani and Sanika Gupte discovered what can protect #HSCs from the deleterious effects of #inflammaging.

Abstract in Nature Aging: https://go.nature.com/3YDag5a

HeartSciences (Nasdaq: HSCS) Q2 shows $2M cash, MyoVista Insights push HeartSciences reports no meaningful FQ2 2026 revenue, ends Oct. 31 with $2M cash and $4.2M equity, and submits MyoVista wavECG device for FDA 510(k).

#HSCS #HSCSW HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

www.stocktitan.net/news/HSCS/heart-sciences...

#HSCS #HSCSW HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

www.stocktitan.net/news/HSCS/heart-sciences...

#HSCS #HSCSW HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

www.stocktitan.net/news/HSCS/heart-sciences...

A Rare Hematopoietic Stem Cell‐Derived Megakaryocyte Progenitor Accumulates via Enhanced Survival and Contributes to Exacerbated Thrombopoiesis Upon Aging Manso et al. developed strategies for isolating and testing the functional mechanisms regulating age-specific megakaryocyte progenitors derived from hematopoietic stem cells.

A little late, but 🚨new paper alert!🚨
Interested in #aging, #blood, #StemCells, #HSCs, #platelets, or #MkPs? Read on!
onlinelibrary.wiley.com/doi/10.1111/...

HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results HeartSciences (NASDAQ: HSCS) reported its Q1 fiscal 2026 results and business updates, highlighting significant progress in its AI-powered ECG technology development. The company successfully launched MyoVista Insights, a cloud-native software platform designed to modernize ECG management systems and serve as an AI-ECG algorithm marketplace.Key developments include receiving FDA Breakthrough Device designation for their aortic stenosis ECG algorithm and expanding their patent portfolio to 44 granted patents worldwide. The company plans to submit their MyoVista wavECG device for FDA 510(k) clearance this calendar year, with separate submissions for device and software algorithm to streamline review.Financially, HeartSciences reported no meaningful revenue for Q1 2026, with $2.8 million in cash and $3.1 million in shareholders' equity as of July 31, 2025. Post-quarter, they raised an additional $0.8 million through a Reg A+ offering and converted $0.7 million of debt to equity.

#HSCS #HSCSW HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

www.stocktitan.net/news/HSCS/heart-sciences...

AI-Powered ECG Technology Company HeartSciences Sets Two Virtual Investor Events for August 2025 HeartSciences to host investor webinar and present at Emerging Growth Conference 85 on August 20. Company to showcase AI-powered ECG technology and provide business updates for investors.

#HSCS #HSCSW HeartSciences Announces Conference Participation and Investor Webinar

www.stocktitan.net/news/HSCS/heart-sciences...

Composite transposons with bivalent histone marks function as RNA-dependent enhancers in cell fate regulation This study reveals that composite transposons with bivalent histone marks can serve as RNA-dependent enhancers, controlling key developmental and aging-related gene programs.

Outstanding paper describing how SVAs are regulated,what's their function in gene regulation and its impact in cell fate

Composite transposons with bivalent histone marks function as RNA-dependent enhancers in cell fate regulation | Cell

#TEs #CellFate #HSCs #Aging

www.cell.com/cell/fulltex...

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results HeartSciences (NASDAQ: HSCS) reported its fiscal 2025 results and business updates, highlighting significant progress in AI-powered ECG technology. The company's flagship MyoVista Insights™ cloud-native software platform launched in May 2025, designed to modernize ECG management systems and serve as a marketplace for AI-ECG algorithms.Key developments include: CMS approval for AI-ECG algorithm reimbursement at $128 per test, FDA Breakthrough Device designation for their aortic stenosis algorithm, and expansion to 44 granted patents worldwide. The company is preparing for FDA 510(k) submission of its MyoVista wavECG™ device and targets FDA submission of its first cloud-based algorithm for detecting reduced ejection fraction in early 2026.Financially, HeartSciences reported $1.1 million in cash as of April 30, 2025, and subsequently raised $3.1 million through a Reg A+ offering and converted $0.9 million of debt to equity.

#HSCS #HSCSW HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

www.stocktitan.net/news/HSCS/heart-sciences...

Thrilled to share with you the latest work from my PhD in Bigas lab at @researchmar.bsky.social @carrerasijc.bsky.social published in @bloodjournal.bsky.social

We’ve programmed blood stem cells from PSCs using CRISPRa screen and found a new “bloody” cocktail

#CRISPR #HSCs #StemCells #CellFate

Revolutionary AI Algorithm Detects Silent Killer Heart Disease 2 Years Earlier, FDA Fast-Tracks Approval AI-powered ECG algorithm identifies aortic stenosis up to 24 months before traditional methods. Seamlessly integrates with hospital systems. See breakthrough results.

#HSCS #HSCSW HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

www.stocktitan.net/news/HSCS/heart-sciences...

Revolutionary AI Patent: HeartSciences Transforms ECG Technology for Earlier Heart Disease Detection New AI-powered ECG technology patent strengthens HeartSciences' 44-patent global portfolio. Breakthrough enables early heart disease detection through ECG analysis. Learn more.

#HSCS #HSCSW Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value

www.stocktitan.net/news/HSCS/foundational-u...

HeartSciences AI-Powered ECG Platform Lands Major NHS Partnership: UK Healthcare Provider Signs First Commercial Deal HeartSciences partners with major UK healthcare provider to deploy AI-powered ECG platform. First commercial deal targets NHS patient care improvement. See rollout details.

#HSCS #HSCSW HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

www.stocktitan.net/news/HSCS/heart-sciences...

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results HeartSciences (HSCS) reported Q3 FY2025 financial results and business updates, highlighting significant progress in AI-powered ECG technology. The company reported no revenues for Q3 FY2025, with cash and cash equivalents of $2.6 million and shareholders' equity of $1.8 million as of January 31, 2025.Key developments include:Final pre-submission meeting with FDA for MyoVista wavECG device in February 2025, with expected FDA clearance submission in H1 2025Successful completion of Phase 1 MyoVista Insights cloud-native platform in December 2024Pre-validation work completed with Rutgers for low ejection fraction algorithmCMS 2025 OPPS final rule inclusion enabling reimbursement upon commercial launchThe company's strategy focuses on modernizing ECG technology through AI-enhanced hardware and software solutions, positioning itself as the only company building next-gen ECG device hardware, device-agnostic cloud-native software, and AI-ECG algorithms.

#HSCS #HSCSW HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

www.stocktitan.net/news/HSCS/heart-sciences...

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications HeartSciences (Nasdaq: HSCS), an AI-powered medical technology company focused on transforming ECGs/EKGs for earlier heart disease detection, has announced its engagement with Integrous Communications to enhance investor relations. The partnership aims to develop and execute a comprehensive investor communications program, leveraging Integrous' expertise in working with leading medical companies.Andrew Simpson, Chairman and CEO, emphasized the importance of maintaining robust investor communications as the company continues its mission of transforming cardiovascular screening through AI-ECG technology. Mark Komonoski, Partner of Integrous Communications, expressed enthusiasm about partnering with HeartSciences to communicate its growth strategy and value proposition to the investment community.

#HSCS #HSCSW HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

www.stocktitan.net/news/HSCS/heart-sciences...

A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones - Leukemia Leukemia - A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones

@ganuzalab.bsky.social
Exciting new work from my former trainee, Mikel Ganuza, now running his own excellent team. Congrats!
#HSCs #clonalhematopoiesis
#science

www.nature.com/articles/s41...

HeartSciences Advances AI-Powered ECG Platform, FDA Submission Set for Q1 2025 HeartSciences prepares for MyoVista wavECG FDA submission as its AI-ECG technology secures CMS reimbursement approval. Key developments reshape cardiac diagnostics future.

#HSCS #HSCSW HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

www.stocktitan.net/news/HSCS/heart-sciences...

The bone marrow 🦴🐭 in the mouse jaw (alveolar bone) holds an unexpectedly high frequency of hematopoietic stem cells - even higher than conventional sources like femur!
Really excited about this new perspective on bone marrow heterogeneity across the body. #HSCs

In August '24: A pool of hematopoietic stem cells, confined to the bone marrow, acquire proteins from macrophages via a process of cell-cell membrane transfer known as trogocytosis.

https://buff.ly/4gbg64J

#HSCs @science.org

So proud of my student presenting her first poster at #ASH24 #BloomSyndrome #raredisease #microbiome #radiation #HSCs